NYMC Faculty Publications
Similar Neurocognitive Outcomes After 48 Weeks in HIV-1-Infected Participants Randomized to Continue Tenofovir/Emtricitabine + Atazanavir/Ritonavir or Simplify to Abacavir/Llamivudine + Atazanavir
Journal Title
Journal of Neurovirology
First Page
22
Last Page
31
Document Type
Article
Publication Date
February 2019
Department
Medicine
Abstract
Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, learning, and working memory in 293 HIV-1-infected, ART-experienced, and virologically suppressed adults. The ASSURE study randomized participants 1:2 to remain on tenofovir/emtricitabine (TDF/FTC) and ritonavir-boosted atazanavir (ATV/r) or simplify to abacavir/lamivudine + atazanavir (ABC/3TC + ATV). Neurocognitive z-scores were computed using demographically adjusted normative data and were classified as "impaired" (defined as either a z-score
Recommended Citation
Robertson, K., Maruff, P., Ross, L., Wohl, D., Small, C., Edelstein, H., & Shaefer, M. (2019). Similar Neurocognitive Outcomes After 48 Weeks in HIV-1-Infected Participants Randomized to Continue Tenofovir/Emtricitabine + Atazanavir/Ritonavir or Simplify to Abacavir/Llamivudine + Atazanavir. Journal of Neurovirology, 25 (1), 22-31. https://doi.org/10.1007/s13365-018-0680-y
